Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group
Authors' conclusion
Our article reports the largest cohort published to date of new-onset IRD following SARS-CoV-2 infection or COVID-19 vaccines. Although causality cannot be ascertained, the spectrum of possible clinical manifestations is broad and includes IJD, PMR, CTD and vasculitis.
Study context
- Population
- Consecutive cases of new-onset inflammatory rheumatic diseases (IRD) after SARS-CoV-2 infection or COVID-19 vaccinationfinal analysis cohort
- Participants
- 267 cases
- Exposure
- Post-COVID-19 vs post-vaccine new-onset IRD
- Post-COVID-19n = 122
- Post-vaccinen = 145
- Outcome
- Spectrum (distribution) of new-onset IRD categories
Methodological detailsmulticentric, consecutive cases, 12-month period
- Multicentric
- Consecutive cases
- 12-month period
Main finding
As reported in the abstract
Inflammatory joint diseases (IJD): Post-COVID-19 vs Post-vaccine
52.5% vs 37.2%
p=0.013
Polymyalgia rheumatica (PMR): Post-vaccine vs Post-COVID-19
33.1% vs 21.3%
p=0.032
Connective tissue diseases (CTD): no difference
19.7% vs 20.7%
p=0.837
Vasculitis: no difference
6.6% vs 9.0%
p=0.467
Observational data: associations, not effects.
Further findings
Response to first-line therapy (drop in baseline disease activity scores)
- IJD
- ≈30%
- PMR
- ≈70%
- Short follow-up period
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →